Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Tislelizumab × Gastrointestinal × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 654 Pancreatic Neoplasms 596 Stomach Neoplasms 346 Carcinoma, Hepatocellular 330 Carcinoma, Non-Small-Cell Lung 326 Breast Neoplasms 284 Colonic Neoplasms 255 Ovarian Neoplasms 230 Neoplasms 225 Esophageal Neoplasms 204 Neoplasm Metastasis 187 Rectal Neoplasms 182 Melanoma 172 Lung Neoplasms 168 Liver Neoplasms 163 Squamous Cell Carcinoma of Head and Neck 133 Carcinoma, Renal Cell 129 Head and Neck Neoplasms 109 Prostatic Neoplasms 104 Triple Negative Breast Neoplasms 97 Uterine Cervical Neoplasms 93 Urinary Bladder Neoplasms 92 Sarcoma 90 Endometrial Neoplasms 85 Cholangiocarcinoma 84 Gastrointestinal Neoplasms 65 Small Cell Lung Carcinoma 64 Esophageal Squamous Cell Carcinoma 61 Kidney Neoplasms 58 Carcinoma, Transitional Cell 49

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04906044 2023-11-18

STARS-RC03

The First Hospital of Jilin University

Phase 1 Active not recruiting

Gastrointestinal

Tislelizumab

Data powered by HemOnc (CC BY 4.0) Colophon ⚡